Clinical trials: Cancer-Related Condition
Lymphoma
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Primary Objective: To evaluate the efficacy of SAR245409 as determined by the objective response rate (ORR) in patients with 1 of following relapsed or refractory lymphoma or leukemia subtypes: mantle cell lymphoma (MCL)…
- Trial name
- NCT01403636
- Testing
- SAR245409
- Where
- 30 sites in United States, Australia and 4 more
- Volunteers
- 167 people
- Sponsor
- Sanofi
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics
Gynaecomastia, Prostate Cancer
Casodex - Nolvadex Combination
This study looks at the relationship in the dose of nolvadex and the incidence of gynaecomastia and also Prostate Specific Antigen (PSA) inhibition when co-administered with Casodex.
- Trial name
- NCT00637871
- Testing
- Casodex, Tamoxifen
- Sponsor
- AstraZeneca
Breast Neoplasms, Osteoporosis
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
This protocol is designed to compare the effect on bone of Zoledronic Acid 4 mg every 6 months when given upfront versus delayed start (based on a post-baseline BMD T- Score below -2.0 SD at either the lumbar spine or total hip…
- Trial name
- NCT00050011
- Testing
- Zoledronic Acid, Letrozole
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 602 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Multiple Myeloma
Velcade Consolidation Bone Study
The purpose of this study is to assess the effect of bortezomib on myeloma-related bone disease, analyzing bone mineral density (BMD) in patients with Multiple Myeloma (MMY) who have received high dose chemotherapy and autologous…
- Trial name
- NCT01286077
- Testing
- bortezomib
- Where
- 21 sites in Austria, Czechia and 6 more
- Volunteers
- 106 people
- Sponsor
- Janssen-Cilag International NV
Stomach Neoplasms
A Phase II Study of Oxaliplatin in Association With 5FU and Folinic Acid in the Treatment of Subjects With Non-Surgical or Advanced Metastatic Gastric Cancer
This phase II trial will evaluate, in first line advanced or metastatic gastric cancer, the efficacy and tolerance of another oxaliplatin, 5FU bolus combination already tested in advanced colorectal cancer
- Trial name
- NCT00611507
- Testing
- Oxaliplatin, 5-Fluorouracil
- Where
- Colombia
- Volunteers
- 21 people
- Sponsor
- Sanofi
Grade 2 Hand-foot Syndrom
Efficacy of the Cosmetic Product "Onco-Repair" on Grade 2 Hand Foot Syndrome
The aim of the study is to assess the restorative efficacy of the cosmetic product "Onco-Repair" vs placebo of the most affected palmer face in subject with grade 2 HFS induced by targeted therapies or conventional chemotherapy.
- Trial name
- OCRP (NCT03612011)
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Quanta Medical
Hepatocellular Carcinoma
A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)
This is a multi-center,open-label study to evaluate the efficacy and safety of anti-PD-1 antibody AK105 plus anlotinib hydrochloride in the first-line treatment of patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT04172571
- Testing
- AK105, Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Akeso
Gastric Ulcer (GU), Duodenal Ulcer (DU)
A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
The objective of this study is to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of repeated once daily oral administration of D961H 10 mg and D961H 20 mg in Japanese paediatric patients aged 1 to 14 years old…
- Conditions
- Gastric Ulcer (GU), Duodenal Ulcer (DU), Anastomotic Ulcer (AU), Non-erosive Reflux Esophagitis Disease (NERD)
- Trial name
- NCT02153398
- Testing
- D961H sachet 10 mg, D961H capsule 10mg, D961H capsule 20 mg
- Where
- 15 sites in Japan
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Sturge-Weber Syndrome (SWS), Glaucoma
A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101
Safety and tolerability study of 2 concentrations of QLS-101 for adult subjects with Sturge Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure (EVP).
- Conditions
- Sturge-Weber Syndrome (SWS), Glaucoma, Glaucoma Congenital, Ocular Hypertension
- Trial name
- NCT04947124
- Testing
- QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2%
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Qlaris Bio, Inc.
Pain, Burning, Pain, Crushing
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain
The purpose of this study is to compare the safety and effectiveness of JNJ-42160443 with placebo in the treatment of chronic, moderate to severe cancer-related pain in terminally ill patients with a diagnosis of active cancer.
- Conditions
- Pain, Burning, Pain, Crushing, Pain, Migratory, Pain, Radiating
- Trial name
- NCT00929188
- Testing
- JNJ-42160443
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 100 people
- Sponsor
- Janssen Research & Development, LLC
Hepatocellular Carcinoma, Solid Tumor
A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene
This is a Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients…
- Conditions
- Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
- Trial name
- MYCHELANGELO I (NCT05497453)
- Testing
- OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two
- Where
- 15 sites in United States, Hong Kong and 3 more
- Volunteers
- 24 people
- Sponsor
- Omega Therapeutics
Advanced Solid Tumors
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
The purpose of the study is to test how well patients with advanced solid tumors respond to treatment with elimusertib (BAY1895344) in combination with pembrolizumab.
- Trial name
- NCT04095273
- Testing
- Elimusertib (BAY1895344), Pembrolizumab (Keytruda®)
- Where
- 16 sites in United States, Germany and 3 more
- Volunteers
- 56 people
- Sponsor
- Bayer
Multiple Sclerosis, Diabetes
An Observational Post-Marketing Safety Registry of Sativex®
The purpose of this registry is to monitor safety outcomes of patients who are receiving Sativex® for Multiple Sclerosis (MS) spasticity and for off-label indications in the United Kingdom (UK), Germany and Sweden.
- Conditions
- Multiple Sclerosis, Diabetes, Cancer, Neuropathic Pain
- Trial name
- NCT02073474
- Testing
- Sativex®
- Volunteers
- 978 people
- Sponsor
- Jazz Pharmaceuticals
Renal Cell Carcinoma
Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents
A retrospective study to evaluate healthcare cost and resource utilization for patients with metastatic renal cell carcinoma who have been treated with IV or oral agents
- Trial name
- NCT02928263
- Testing
- Non-Interventional
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Opioid-Induced Constipation
Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain
The purpose of this study is to compare the effect of NKTR-118 with placebo in the treatment of opioid-induced constipation (OIC) in patients with cancer-related pain, including those patients that have inadequate response to…
- Trial name
- NCT01384292
- Testing
- NKTR-118
- Where
- 140 sites in United States, Australia and 12 more
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Metastatic Melanoma
Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma
This is a global, Phase 2, open label, dose selection, proof-of-concept study to assess progression free survival in subjects with metastatic melanoma.
- Trial name
- NCT01335009
- Testing
- MORAb-004 (monoclonal antibody)
- Where
- 29 sites in United States, Australia and 2 more
- Volunteers
- 76 people
- Sponsor
- Eisai Inc.
Cancer Related Pain (Breakthrough Pain)
A Comparative Study of KW-2246
This is a placebo-controlled, double blind, comparative study to evaluate the efficacy and safety of KW-2246 as rescue medication at an optimal dose, which is determined by dose titration in treating breakthrough pain episodes in…
- Trial name
- 2246-004 (NCT01326689)
- Testing
- KW-2246
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Prostate Cancer
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
The purpose of this study is to find out in the real-world setting, if darolutamide is safe and effective for patients diagnosed with prostate cancer that has not spread to other parts of the body.
- Trial name
- DAROL (NCT04122976)
- Testing
- Darolutamide(Nubeqa, BAY1841788)
- Where
- 40 sites in United States, Argentina and 15 more
- Volunteers
- 805 people
- Sponsor
- Bayer